FAP and cancer: Using radiolabelled FAP-Inhibitors (FAPI) FAPI-02 and FAPI-04, the Haberkorn group demonstrated proof of concept for the clinical use of 68Ga-labeled FAPI PET/CT in various cancers with significant lower background uptake in the liver and brain compared to 18F-FDG [68,69].